Illumina (ILMN) stock
Last close $192.82 on 2026-11-20 (-3.90%) · Sector: Healthcare
Illumina is a healthcare company that makes machines and chemical kits used by labs and researchers to read and analyze DNA, the genetic code inside living things. It mainly makes money by selling these instruments and the recurring supplies, such as reagents, that they use, along with related services.
Illumina's business is growing slowly, with revenue up 6.1% over the last year and profit margins that are healthy but not especially high. The stock has still beaten the S&P 500 over the past year, returning 55.7% versus 4.7%. The share price is 37.7% below its 52-week high and 22.3% below its 50-day average, while sitting 6.5% above its 200-day average. Insiders, mainly director Keith Meister, sold about $270.1M of stock in the last 90 days and made no purchases, and the stock has moved sharply after past earnings reports.
Key numbers
- Market cap: $29.7B
- Revenue (last 12 months): $4.54B
- Revenue growth: +6.1%
- Gross margin: 67.9%
- Operating margin: 20.9%
- P/E: 33.2
- P/S: 6.5
- Debt to equity: 0.21
- Current ratio: 2.62
Quality score
Overall 38/100 · growth 35 · profitability 45 · financial health 73 · value 0
Performance and risk
1-year return +55.7% vs S&P 500 +4.7% · volatility 49.2% (S&P 500 14.3%) · largest drop -34.4% · beta 1.11
Stock move the day after earnings
- 2026-01-13: +1.0%
- 2026-02-05: -10.4%
- 2026-04-30: +7.1%
- 2026-07-30: +0.0%
- 2026-10-29: -18.6%
Congress trades (90 days)
0 buys, 1 sells
Insider trades (12 months)
Bought $0.0M · sold $720.4M
ILMN stock research · ILMN options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.